Department of Head and Neck Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan.
Ann Nucl Med. 2013 Apr;27(3):297-302. doi: 10.1007/s12149-013-0686-8. Epub 2013 Jan 22.
We investigated the relationship between overall survival of patients and pretreatment [(18)F]-2-fluorodeoxyglucose ((18)F-FDG) uptake, assessed by positron emission tomography combined with computed tomography (PET/CT) in hypopharyngeal squamous cell carcinoma.
Thirty-one patients who were newly diagnosed as resectable hypopharyngeal squamous cell carcinoma underwent pretreatment (18)F-FDG-PET/CT. We used the maximum standardized uptake value (SUVmax) as (18)F-FDG uptake. Overall survival rate was calculated by the Kaplan-Meier method.
The median SUVmax was 11.53 (range 2.49-22.33). Patients with SUVmax ≥ 13 significantly exhibited shorter overall survival in univariate analysis (p < 0.01). Moreover, by Cox proportional hazards model of multivariate analysis, SUVmax ≥ 13 was a significant prognostic factor independent of clinical T and N classification, and treatment group (p < 0.02).
These results suggested that SUVmax obtained by pretreatment (18)F-FDG PET/CT assessment is an important prognostic factor in patients with hypopharyngeal squamous cell carcinoma.
我们通过正电子发射断层扫描与计算机断层扫描（PET/CT），研究了下咽鳞癌患者的总生存率与治疗前（18）F-2-氟脱氧葡萄糖摄取之间的关系。
31 例新诊断为可切除性下咽鳞癌患者在治疗前进行了（18）F-FDG-PET/CT 检查。我们使用最大标准化摄取值（SUVmax）作为（18）F-FDG 摄取。采用 Kaplan-Meier 方法计算总生存率。
SUVmax 的中位数为 11.53（范围 2.49-22.33）。单因素分析显示，SUVmax≥13 的患者总生存率明显较短（p<0.01）。此外，通过多因素分析的 Cox 比例风险模型，SUVmax≥13 是独立于临床 T 和 N 分类以及治疗组的重要预后因素（p<0.02）。
这些结果表明，治疗前（18）F-FDG PET/CT 评估获得的 SUVmax 是下咽鳞癌患者的一个重要预后因素。
